Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Danoprevir - Array BioPharma/Roche/Ascletis

Drug Profile

Danoprevir - Array BioPharma/Roche/Ascletis

Alternative Names: ASC-08; Ganovo; ITMN-191; ITMN-B; R-7227; RG-7227; RO-5190591

Latest Information Update: 25 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Array BioPharma; InterMune
  • Developer Ascletis; Roche
  • Class Antivirals; Carboxylic acids; Cyclopropanes; Isoindoles; Macrocyclic compounds; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C
  • Clinical Phase Unknown COVID 2019 infections

Most Recent Events

  • 25 Aug 2020 Danoprevir is launched for Hepatitis C (combination therapy, treatment Naïve) in China (PO)
  • 24 Mar 2020 Safety and efficacy data from clinical trial in COVID-2019 infections released by Ascletis Pharma
  • 18 Mar 2020 Ascletis Pharmaceutical initiates phase IV trial for COVID-2019 infections (Combination therapy) in China (PO) (NCT04345276)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top